Quick Answer
Urolithin A Exercise Performance Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Individuals with sarcopenia face a significantly elevated risk of falls, fractures, cognitive impairment, and functional dependency, leading to increased hospitalization rates, prolonged lengths of stay, and greater healthcare costs [,,].
Key Takeaways
- 01Individuals with sarcopenia face a significantly elevated risk of falls, fractures, cognitive impairment, and functional dependency, leading to increased hospitalization rates, prolonged lengths of stay, and greater healthcare costs [,,]. [Chin Hui San (2026)]
- 02These disruptions converge on key processes such as reduced neuromuscular integrity, impaired energy metabolism, and blunted anabolic signaling, ultimately contributing to declines in muscle strength and function. [Chin Hui San (2026)]
- 03As a narrative synthesis, formal systematic review methodology and risk-of-bias assessment, were not applied. [Chin Hui San (2026)]
- 041 2 3 4 5 6 7 3 Sarcopenia, defined as the progressive loss of skeletal muscle mass and function, is widely acknowledged as a critical determinant of health outcomes in aging populations and patients with chronic disease. [Chin Hui San (2026)]
The current Migaku evidence database contains 2 reusable source documents for Urolithin A Exercise Performance Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Individuals with sarcopenia face a significantly elevated risk of falls, fractures, cognitive impairment, and functional dependency, leading to increased hospitalization rates, prolonged lengths of stay, and greater healthcare costs [,,]. [Chin Hui San (2026); evidence level 4]
- These disruptions converge on key processes such as reduced neuromuscular integrity, impaired energy metabolism, and blunted anabolic signaling, ultimately contributing to declines in muscle strength and function. [Chin Hui San (2026); evidence level 4]
- As a narrative synthesis, formal systematic review methodology and risk-of-bias assessment, were not applied. [Chin Hui San (2026); evidence level 4]
- 1 2 3 4 5 6 7 3 Sarcopenia, defined as the progressive loss of skeletal muscle mass and function, is widely acknowledged as a critical determinant of health outcomes in aging populations and patients with chronic disease. [Chin Hui San (2026); evidence level 4]
- Proteomic screening of skeletal muscle biopsies revealed UA upregulated pathways associated with mitochondria, while downregulating inflammatory pathways. [Whitfield J (2025); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources